Novocure™ Announces National Reimbursement for Optune® in Austria
August 08 2017 - 9:25AM
Business Wire
The decision marks Novocure’s first national coverage policy
Novocure (NASDAQ: NVCR) announced today it has signed a contract
with the Federation of the Austrian Social Insurance Institutions
which grants reimbursement across Austria for Optune – Novocure’s
Tumor Treating Fields (TTFields) delivery system – for the
treatment of adults with newly diagnosed glioblastoma (GBM). All 18
Austrian insurance funds have agreed to participate in the
contract.
“This decision marks Novocure’s first national reimbursement for
Optune, providing additional access to millions of people,” said
Novocure CEO Asaf Danziger. “Access to our therapy continues to
grow, demonstrating health insurers’ increasing recognition of
Optune.”
With a defined reimbursement pathway now established in Austria,
Novocure’s efforts will turn to increasing adoption. Novocure
estimates approximately 280 people are diagnosed with GBM or tumors
that typically progress to GBM in Austria each year. Of this
population, Novocure estimates that approximately 210 patients are
candidates for treatment with Optune based upon the rate of disease
progression and medical eligibility.
About Novocure
Novocure is an oncology company developing a profoundly
different cancer treatment utilizing a proprietary therapy called
TTFields, the use of electric fields tuned to specific frequencies
to disrupt solid tumor cancer cell division. Novocure’s
commercialized product, Optune, is approved for the treatment of
adult patients with glioblastoma. Novocure has ongoing or completed
clinical trials investigating TTFields in brain metastases,
non-small cell lung cancer, pancreatic cancer, ovarian cancer and
mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in
Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City.
Additionally, the company has offices in Germany, Switzerland,
Japan and Israel. For additional information about the company,
please visit www.novocure.com or follow us at
www.twitter.com/novocure.
About Optune
In the United States, Optune is intended as a treatment for
adult patients (22 years of age or older) with
histologically-confirmed glioblastoma multiforme (GBM).
In the United States, Optune with temozolomide is indicated for
the treatment of adult patients with newly diagnosed,
supratentorial glioblastoma following maximal debulking surgery and
completion of radiation therapy together with concomitant standard
of care chemotherapy.
In the United States, for the treatment of recurrent GBM, Optune
is indicated following histologically-or radiologically-confirmed
recurrence in the supratentorial region of the brain after
receiving chemotherapy. The device is intended to be used as a
monotherapy, and is intended as an alternative to standard medical
therapy for GBM after surgical and radiation options have been
exhausted.
In the European Union, Optune is intended for the treatment of
patients with newly diagnosed GBM, after surgery and radiotherapy
with adjuvant temozolomide, concomitant to maintenance
temozolomide. The treatment is intended for adult patients, 18
years of age or older, and should be started more than 4 weeks
after surgery and radiation therapy with adjuvant temozolomide.
Treatment may be given together with maintenance temozolomide and
after maintenance temozolomide is stopped.
In the European Union, Optune is also intended for the treatment
of patients with recurrent GBM who have progressed after surgery,
radiotherapy and temozolomide treatment for their primary disease.
The treatment is intended for adult patients, 18 years of age or
older, and should be started more than 4 weeks after the latest
surgery, radiation therapy or chemotherapy.
Patients should only use Optune under the supervision of a
physician properly trained in use of the device. Full prescribing
information is available at www.optune.com/safety or by calling
toll free 1-855-281-9301 in the US or by email at
supportEMEA@novocure.com in the European Union.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as “anticipate,” “estimate,” “expect,” “project,” “intend,”
“plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2017, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170808005881/en/
NovocureMedia and Investor Contact:Ashley
Cordova212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024